A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

December 22, 2022

Study Completion Date

December 31, 2026

Conditions

Allergic to House Dust Mites

Interventions

BIOLOGICAL

ASP2390

Intradermal

BIOLOGICAL

Placebo

Intradermal; normal saline solution

Trial Locations (2)

Site DE49001, Berlin

Site DE49002, Hanover

All Listed Sponsors

lead

Astellas Pharma Global Development, Inc.

INDUSTRY